CN117815276A - Application of lactobacillus BB1 for improving sweet perception capability - Google Patents
Application of lactobacillus BB1 for improving sweet perception capability Download PDFInfo
- Publication number
- CN117815276A CN117815276A CN202311741875.2A CN202311741875A CN117815276A CN 117815276 A CN117815276 A CN 117815276A CN 202311741875 A CN202311741875 A CN 202311741875A CN 117815276 A CN117815276 A CN 117815276A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- mice
- individual
- medicament
- sweet taste
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000186660 Lactobacillus Species 0.000 title claims abstract description 86
- 229940039696 lactobacillus Drugs 0.000 title claims abstract description 86
- 230000008447 perception Effects 0.000 title claims description 27
- 235000009508 confectionery Nutrition 0.000 title description 15
- 235000019605 sweet taste sensations Nutrition 0.000 claims abstract description 26
- 239000002858 neurotransmitter agent Substances 0.000 claims abstract description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 14
- 239000008103 glucose Substances 0.000 claims abstract description 14
- 230000030738 sensory perception of sweet taste Effects 0.000 claims abstract description 14
- 210000004556 brain Anatomy 0.000 claims abstract description 13
- 208000008589 Obesity Diseases 0.000 claims abstract description 11
- 239000008280 blood Substances 0.000 claims abstract description 11
- 210000004369 blood Anatomy 0.000 claims abstract description 11
- 235000020824 obesity Nutrition 0.000 claims abstract description 11
- 108091005708 gustatory receptors Proteins 0.000 claims abstract description 10
- 230000006866 deterioration Effects 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 27
- 230000000694 effects Effects 0.000 claims description 19
- 210000003750 lower gastrointestinal tract Anatomy 0.000 claims description 8
- 108020004999 messenger RNA Proteins 0.000 claims description 8
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims description 8
- 210000000087 hemolymph Anatomy 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 101000659765 Homo sapiens Taste receptor type 1 member 2 Proteins 0.000 claims description 6
- 101000659774 Homo sapiens Taste receptor type 1 member 3 Proteins 0.000 claims description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 6
- 102100035948 Taste receptor type 1 member 2 Human genes 0.000 claims description 6
- 102100035942 Taste receptor type 1 member 3 Human genes 0.000 claims description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 4
- 239000005700 Putrescine Substances 0.000 claims description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims description 4
- 229960004373 acetylcholine Drugs 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- 229960003767 alanine Drugs 0.000 claims description 3
- 239000003674 animal food additive Substances 0.000 claims description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 3
- 229960004441 tyrosine Drugs 0.000 claims description 3
- 230000033228 biological regulation Effects 0.000 claims description 2
- 230000002222 downregulating effect Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 4
- 238000004321 preservation Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 39
- 241000256837 Apidae Species 0.000 abstract description 21
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 21
- 238000013116 obese mouse model Methods 0.000 abstract description 16
- 238000002474 experimental method Methods 0.000 abstract description 7
- 150000001413 amino acids Chemical class 0.000 abstract description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 244000005700 microbiome Species 0.000 abstract description 4
- 241000193830 Bacillus <bacterium> Species 0.000 abstract description 3
- 239000004310 lactic acid Substances 0.000 abstract description 3
- 235000014655 lactic acid Nutrition 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 2
- 208000027418 Wounds and injury Diseases 0.000 abstract description 2
- 230000006378 damage Effects 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 208000014674 injury Diseases 0.000 abstract description 2
- 230000004060 metabolic process Effects 0.000 abstract description 2
- 230000014860 sensory perception of taste Effects 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 239000000243 solution Substances 0.000 description 15
- 229930006000 Sucrose Natural products 0.000 description 14
- 239000005720 sucrose Substances 0.000 description 14
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 12
- 230000000968 intestinal effect Effects 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 9
- 230000002354 daily effect Effects 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 241000257303 Hymenoptera Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000014101 glucose homeostasis Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000008054 signal transmission Effects 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 125000000185 sucrose group Chemical group 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 2
- 239000001393 triammonium citrate Substances 0.000 description 2
- 235000011046 triammonium citrate Nutrition 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 238000013218 HFD mouse model Methods 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000006583 body weight regulation Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000011217 control strategy Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000001339 gustatory effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000004280 healthy diet Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000021070 high sugar diet Nutrition 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000021147 sweet food Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001779 taste bud Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Physiology (AREA)
- Child & Adolescent Psychology (AREA)
- Animal Husbandry (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to the technical field of microorganisms, in particular to application of lactobacillus BB1 in improving sweet taste perception capability. In the bumblebee animal experiment, the administration of the lactobacillus BB1 can obviously improve the sweet taste perception capability of a host, promote the metabolism of amino acid in intestinal tracts and influence the neurotransmitter content of brain; in the animal experiments of mice, the lactic acid bacillus BB1 provided by the invention can obviously improve the sweet taste perception capability of obese mice and diabetic mice, reduce the weight of the obese mice, improve the blood glucose steady state of the obese mice and influence the sweet taste receptor expression of the tongue of the mice. Therefore, the lactobacillus BB1 capable of enhancing the sweet taste perception capability of an individual can be used for relieving and treating taste deterioration or accompanying taste perception injury caused by diseases such as obesity, diabetes and the like, can be used for preventing and treating the diseases such as the obesity, the diabetes and the like, can assist the individual to realize blood sugar control, and has a very wide application prospect.
Description
Technical Field
The invention relates to the technical field of microorganisms, in particular to application of lactobacillus BB1 in improving sweet taste perception capability.
Background
Sweet taste is the nature of humans, and eating sweet food is one of the decompression modes of many modern people, but with the improvement of healthy diet consciousness of people, the control of sugar intake is a topic of increasing attention. Metabolic diseases, such as diabetes, obesity, cardiovascular diseases, fatty liver, cancer, etc., which are mainly characterized by imbalance in glycolipid metabolic homeostasis due to consumption of high sugar products in large quantities, have been severely threatening the health of humans. Taking diabetes as an example, obesity in excess caused by aging of the population and lack of exercise in long-term high-sugar diet is a major cause of epidemic disease in the world for type II diabetes. Therefore, various countries around the world are developing sugar-reducing and sugar-controlling exercises, and reducing sugar in foods has become one of the technical challenges of the food industry.
The intestinal flora has strong metabolic capacity and plays an important role in the digestion of carbohydrates in the intestinal tract. Earlier studies have linked intestinal flora to neural behaviour and have proposed the concept of intestinal (flora) -the brain axis, i.e. intestinal microorganisms and their metabolites can have profound effects on host brain function and behaviour. For example, several studies have found that intestinal bacteria can affect the memory and mood of a host; muramyl peptide of enterobacteria can regulate body weight and body temperature of mice by affecting specific neurons in the brain; the intestinal bacteria can regulate sensory decisions of a host, influence the response of the intestinal bacteria to odor and the like and select food. Furthermore, the intestinal flora may influence the perception of sweetness by the host. Therefore, the influence of the intestinal flora on the perception of sweet taste of a host is a feasible novel sugar reduction and control strategy.
Studies have shown that obese patients, diabetics have a different degree of reduced perception of sweetness than healthy individuals, and that this reduced perception of taste may promote their intake of more sugar or sweeter foods to meet taste demands, thereby re-aggravating body weight, blood glucose. However, there is currently a lack of microbial agents and drugs that regulate host sweet perception by modulating intestinal flora. Therefore, it is important to screen probiotics capable of improving the sweetness perception capability of individuals and develop medicaments for assisting in reducing and controlling sugar.
Disclosure of Invention
Most probiotics known at present have the effects of regulating constipation, improving enteritis, relieving lactose intolerance, improving intestinal functions and the like, but no research reports that certain probiotics can improve the sweet perception capability of a host. The invention provides application of lactobacillus BB1 in improving individual sweet perception capability, and aims to screen lactobacillus capable of improving individual sweet perception capability and develop auxiliary sugar-reducing and sugar-controlling related medicines and feed additives.
The first technical scheme provided by the invention is application of lactobacillus BB1 in preparing a product for improving sweet perception capability.
In one embodiment of the present invention, the Lactobacillus (Lactobacillus Firm-5) BB1 was deposited at 25 months 2021 with the microorganism culture Collection of Guangdong province under the accession number GDMCC No. 61578, with the accession number of Guangzhou Hirship 100, hirship, highway No. 59, building 5, guangdong province, disclosed in the patent publication No. CN 113122473A.
In one embodiment of the invention, the effect of improving sweetness perception comprises the following effects:
(1) Reducing the content of glutamine and serine in the hindgut and haemolymph of the individual;
(2) Altering neurotransmitter content in the brain of an individual.
In one embodiment of the invention, the effect of altering neurotransmitter content in the brain of the individual comprises: up-regulating the neurotransmitters acetylcholine, L-tyrosine, gamma-aminobutyric acid and/or putrescine, and down-regulating the neurotransmitters L-alanine and/or 5-hydroxytryptamine.
In one embodiment, the product is a pharmaceutical or feed additive.
In one embodiment, the medicament further comprises a pharmaceutically acceptable carrier.
In one embodiment, the carrier comprises one or more of fillers, binders, humectants, disintegrants, lubricants, flavoring agents commonly used in medicine.
Further, the dosage forms of the medicine comprise granules, capsules, tablets, pills or oral liquids.
Still further, the medicament comprises tablets, capsules and oral liquid which are coated with enteric coatings through mouth.
In one embodiment, the live bacteria count of the lactobacillus BB1 in the medicament is not less than 1×10 6 CFU/mL or 1X 10 6 CFU/g。
Further, the viable count of the lactobacillus BB1 in the medicament is not less than 1×10 8 CFU/mL or 1X 10 8 CFU/g。
The second technical scheme provided by the invention is a medicament for improving the sweetness perception capability of an individual, wherein the medicament contains lactobacillus BB1, and the storage number of the lactobacillus BB1 is GDMCC No. 61578.
In one embodiment, the live bacteria count of the lactobacillus BB1 in the medicament is not less than 1×10 6 CFU/mL or 1X 10 6 CFU/g。
Further, the viable count of the lactobacillus BB1 in the medicament is not less than 1×10 8 CFU/mL or 1X 10 8 CFU/g。
The third technical scheme provided by the invention is the application of lactobacillus BB1 in preparing a medicament for preventing and/or treating obesity.
The fourth technical scheme provided by the invention is application in medicines for regulating individual blood sugar.
In one embodiment, the live bacteria count of the lactobacillus BB1 in the medicament is not less than 1×10 6 CFU/mL or 1X 10 6 CFU/g。
Further, the viable count of the lactobacillus BB1 in the medicament is not less than 1×10 8 CFU/mL or 1X 10 8 CFU/g。
The fifth technical scheme provided by the invention is application of lactobacillus BB1 in preparing medicines for relieving and treating individual taste deterioration.
In one embodiment, the application includes the following actions: up-regulating mRNA expression of sweet taste receptors T1R2, T1R3 in an individual.
In one embodiment, the taste deterioration is caused by obesity, diabetes, or a cold.
In one embodiment, the live bacteria count of the lactobacillus BB1 in the medicament is not less than 1×10 6 CFU/mL or 1X 10 6 CFU/g。
Further, the viable count of the lactobacillus BB1 in the medicament is not less than 1×10 8 CFU/mL or 1X 10 8 CFU/g。
The fifth technical scheme provided by the invention is a pharmaceutical additive, wherein the pharmaceutical additive contains the lactobacillus BB1.
In one embodiment, the live bacteria count of the lactobacillus BB1 in the pharmaceutical additive is not less than 1×10 6 CFU/mL or 1X 10 6 CFU/g。
Further, the viable count of the lactobacillus BB1 in the pharmaceutical additive is not less than 1×10 8 CFU/mL or 1X 10 8 CFU/g。
The beneficial effects are that:
in the bumblebee animal experiment, the lactic acid bacillus BB1 can obviously improve the sweet taste perception capability of a host, promote the metabolism of amino acids in intestinal tracts, improve the content of beneficial substances such as glutamine and the like related to cognition in blood, influence the neurotransmitter content of the brain, and influence the brain nerve signal transmission by improving the content of neurotransmitters such as acetylcholine, putrescine and the like; in the animal experiments of mice, the lactic acid bacillus BB1 provided by the invention can obviously improve the sweet taste perception capability of obese mice and diabetic mice, reduce the weight of the obese mice, improve the blood glucose steady state of the obese mice and influence the sweet taste receptor expression of the tongue of the mice. Therefore, the lactobacillus BB1 capable of enhancing the sweet taste perception capability of an individual can be used for relieving and treating taste deterioration or accompanying taste perception injury caused by diseases such as obesity, diabetes and the like, can be used for preventing and treating the diseases such as the obesity, the diabetes and the like, can assist the individual to realize blood sugar control, and has a very wide application prospect.
Drawings
FIG. 1 shows the effect of Lactobacillus BB1 on the sucrose perception of bumblebee. Lactobacillus BB1 can obviously improve the perception capability of a host to sugar water; * P <0.001.
FIG. 2 is a quantification of several major bacteria in bumblebee hindgut after feeding Lactobacillus BB 1; * P <0.0001.
FIG. 3 shows the effect of Lactobacillus BB1 on bumblebee intestinal tract and haemolymph amino acids. (a) differences in hindgut amino acids; (B) differences in the haemolymph amino acids.
FIG. 4 is a graph showing the effect of Lactobacillus BB1 on bumblebee brain neurotransmitters; (a) results of principal component analysis; (B) results of differential analysis.
FIG. 5 is the effect on sucrose preference in mice after feeding Lactobacillus BB 1; * P <0.05.
FIG. 6 is the effect on mouse body weight and glucose tolerance after feeding Lactobacillus BB 1; (a) body weight; (B) glucose tolerance detection; * P <0.01.
FIG. 7 shows the expression of mRNA from tongue tissue of mice after feeding Lactobacillus BB 1; (a) T1R2 mRNA expression; (B) T1R3 mRNA expression; * P <0.05.
FIG. 8 is the effect of feeding Lactobacillus BB1 on sucrose preference in diabetic mice; * P <0.05.
Detailed Description
The present invention will be further described in detail below with reference to specific embodiments and with reference to the accompanying drawings, in order to make the objects, technical solutions and advantages of the present invention more obvious and understandable.
The following examples relate to the following media:
MRS solid medium: 10.00g/L of tryptone, 5.00g/L of yeast extract, 10.00g/L of beef extract, 20.00g/L of glucose, 2.00g/L of triammonium citrate, 5.00g/L of anhydrous sodium acetate, 0.10g/L of magnesium sulfate, 0.05g/L of manganese sulfate, 2.00g/L of dipotassium hydrogen phosphate, 1.00mL/L of tween 80, 15.00g/L of agar powder and pH of a culture medium of 6.5 are adjusted.
MRS liquid medium: 10.00g/L tryptone, 5.00g/L yeast extract, 10.00g/L beef extract, 20.00g/L glucose, 2.00g/L triammonium citrate, 5.00g/L anhydrous sodium acetate, 0.10g/L magnesium sulfate, 0.05g/L manganese sulfate, 2.00g/L dipotassium hydrogen phosphate, 1.00mL/L Tween 80 and pH of the culture medium adjusted to 6.5.
Example 1 Effect of Lactobacillus BB1 on the sweet perception ability of bumblebee individuals
The activated lactobacillus is inoculated in an inoculum size of 0.4 percent in MRS liquid culture medium, and is cultured in an anaerobic environment at 37 ℃ for 48 hours. Centrifuging fresh stationary phase bacterial culture solution (6000 g,5 min) to remove supernatant, washing thallus twice with PBS, precipitating the thallus in 40% (w/w) sucrose water, and re-suspending to reach bacterial concentration OD 600 ＝1.0。
The worker bees newly coming out of the house are marked every day, and transferred to different small wooden boxes for grouping feeding at the age of 3 days, and 2 groups of 15 bees are added in each group, and the specific grouping conditions are as follows: (1) control group: providing 40% (w/w) sucrose water daily; (2) lactobacillus BB1 feeding group: providing a daily new formulation containing Lactobacillus BB1 (OD 600 40% sucrose water of=1), feeding for 9 days.
When bumblebee is 12 days old, the bumblebee is fasted for 12 hours and then subjected to a sweet perception test, and the specific test method and the specific test result are as follows:
mu.l of water (0%) and fifteen different concentrations of sugar water (0.1%, 0.25%, 0.5%, 0.75%, 1%, 1.25%, 1.5%, 2%, 2.5%, 3%, 4%, 5%, 10%, 30%, 40%) were sequentially supplied to the fasted bumblebees, and the feeding of the bumblebees was observed and recorded. At different concentration test intervals, clean water and alcohol cotton balls with the concentration of 75% are used for cleaning and wiping the test areas, so that no smell or sugar water residue is ensured to influence the test results. As shown in fig. 1, compared with the control group, the sweet taste perception ability of bumblebees can be significantly improved by feeding lactobacillus BB1, and the concentration of individual response to sugar water is reduced, namely more individuals respond to low-concentration sugar water.
After the behavior experiment is finished, the hindgut of bumblebees is collected and used for quantitative analysis of intestinal flora, and the result is shown in figure 2, and the lactobacillus BB1 is fed to remarkably improve the abundance of the bumblebees in the intestinal tract, but the total bacterial load of the intestinal tract is not influenced.
Example 2 Effect of Lactobacillus BB1 on host amino acid metabolism
Bumblebees of the control group (40% sucrose water provided daily) and lactobacillus BB1 fed group were placed on dry ice for choking, followed by dissection to extract the hindgut tissue and haemolymph of the bumblebees. The tissue samples were weighed with analytical balance and the weights were recorded in detail, 500. Mu.l of 5% trichloroacetic acid (m/v) was added, the samples were subjected to tissue disruption in a full-automatic sample mill, and after mixing the samples, they were sonicated at room temperature for 20min and allowed to stand for at least 2h to precipitate proteins. The sample was centrifuged at 15000rpm at 25℃for 30min, and the supernatant was filtered with a 0.22 μm water film and subjected to HPLC on-machine detection.
The results showed that feeding lactobacillus BB1 can reduce the contents of various amino acids such as glutamine, serine and the like in the hindgut and haemolymph of bumblebees (FIG. 3). Glutamine and glutamic acid can mutually convert in vivo, and glutamic acid plays an important role in taste bud receptors and in the gustatory information transmission and regulation process of a higher nerve center. Serine has neuroprotective effects and plays an important role in maintaining brain function, and studies have shown that serine is associated with type 1 diabetes morbidity, blood glucose and weight regulation. Therefore, lactobacillus BB1 can improve the sweet taste perception capability of individuals by regulating the content of glutamine and serine in the hindgut and haemolymph of bumblebees.
Example 3 Effect of Lactobacillus BB1 on the neurotransmitter content in the brain of a host
Bumblebees of the control group (40% sucrose water provided daily) and lactobacillus BB1 fed group were subjected to choking on dry ice, followed by dissection to extract the brain tissue of the bumblebees. Taking a proper amount of sample to be measured in an EP tube, and adding steel balls; acetonitrile and water containing 0.1% formic acid are added, and vortex mixing is uniform; homogenizing for 4 minutes, performing ice water bath ultrasonic treatment for 5 minutes, and repeating the step of homogenizing ultrasonic treatment for 3 times; the samples were allowed to settle overnight at-20 ℃; centrifuging the sample at 4 ℃ and 12000rpm for 15min, and collecting supernatant; supernatant and Na 2 CO 3 Mixing with 2% L-BzCl, and incubating at room temperature for 30min; taking derived supernatant and adding an internal standard; the sample is centrifuged at 12000rpm at 4 ℃ for 15min, and the treated sample is taken and added with water with a certain proportion for HPLC-MS on-machine detection.
The results show that feeding lactobacillus BB1 can significantly alter the neurotransmitter content of the host brain (FIG. 4A, principal component analysis results show that two groups can be distinguished), wherein neurotransmitters with a tendency to up-regulate include acetylcholine, L-tyrosine, gamma-aminobutyric acid, putrescine, etc., and neurotransmitters with a tendency to down-regulate include L-alanine, 5-hydroxytryptamine, etc. (FIG. 4B). This shows that lactobacillus BB1 can enhance the sweetness perception of individuals by altering the neurotransmitter content of bumblebee brain.
Example 4 Lactobacillus BB1 improves sweet perception in obese mice
In this example, 24C 57BL/6J male mice were selected, and the mice were randomly divided into three groups (n=8) including a normal group, an obese group and an obese+Lactobacillus BB1 group. Normal mice were fed with normal feed for 12 weeks, obese mice and obese+lactobacillus BB1 mice were fed with high-fat feed for 12 weeks; the mice of the group of obesity + lactobacillus BB1 were subjected to the intervention of lactobacillus BB1 from week 9, and were gavaged daily with lactobacillus BB1 (OD 600 0.2ml of PBS solution of=1), while mice of normal group and obese group were subjected to intragastric lavage with equal volume of physiological saline daily.
The sugar preference experiment is carried out on each group of mice, two identical drinking water bottles are placed in each cage, one bottle is sucrose solution, the concentration is set to be 1, 5, 10, 15, 20, 25, 50 and 100mmol/L respectively, the other bottle is deionized water, the solution amounts in the two bottles are kept consistent, the double-tube position is exchanged every 24 hours to avoid errors caused by position preference, and each sugar solution concentration is tested for 48 hours. The concentration of the solution was measured from low to high. The results showed that the preference rate of obese mice for lower concentration sucrose solutions was reduced compared to normal mice, whereas feeding lactobacillus BB1 could significantly increase its preference rate for lower concentration sucrose solutions, and it was seen that the sweet perception of obese mice was reduced, whereas lactobacillus BB1 could improve the sweet perception of obese mice (fig. 5).
Example 5 Lactobacillus BB1 can improve obesity symptoms in individuals
Comparison of body weight and glucose tolerance was performed on three groups of mice in example 4, and the high fat diet for 8 weeks allowed the group of mice to have significantly higher body weight than the normal feed group of mice, and subsequent supplementation with lactobacillus BB1 slowed the increase in body weight caused by the high fat diet (fig. 6A). Glucose tolerance assays were further performed to assess the effect of lactobacillus BB1 on glucose homeostasis. Obese mice exhibited a marked glucose tolerance decline, while supplementation with lactobacillus BB1 improved glucose tolerance in obese mice (fig. 6B). The results show that the lactobacillus BB1 has good effects of reducing weight and improving blood glucose homeostasis.
Example 6 Lactobacillus BB1 affects the sweet taste receptor of mouse tongue
mRNA expression of sweet taste receptors T1R2 and T1R3 in the tongue of the mice in example 4 was detected by a real-time fluorescent quantitative PCR method. The results showed that the expression of mRNA in tongue T1R2 and T1R3 was increased in obese mice compared with normal mice, and the expression of mRNA in tongue T1R2 and T1R3 was decreased after supplementation with Lactobacillus BB1, which was similar to that in normal mice (FIG. 7). After the individual eats, the signal transmission and the sweet taste perception are carried out through the sweet taste receptor, and the expression of the sweet taste receptor of the obese mice is disordered, the sweet taste perception capability is impaired, and the expression of the sweet taste receptor of the mice is restored after lactobacillus BB1 is supplemented, so that the lactobacillus BB1 can regulate the sweet taste perception of the obese mice by influencing the expression of the sweet taste receptor.
Example 7 Lactobacillus BB1 can improve sweet perception ability of diabetic mice
In the embodiment, 30C 57BL/6 male mice are selected, and the mice are randomly divided into a normal control group (10 mice) and a high-fat feed group (20 mice), wherein the normal feed is fed to the control group, and the high-fat feed group is fed to the high-fat feed. High-fat diet mice were fed for 10 weeks, and single intraperitoneal injection of Streptozotocin (STZ, 50 mg/kg) induced diabetes to obtain diabetic mice. Wherein 10 diabetic mice were not given lactobacillus intervention, a diabetic group; another 10 diabetic mice were given Lactobacillus BB1 intervention, and were gavaged daily with Lactobacillus BB1 (OD 600 Physiological saline 0.2ml of =1), total intervention for 4 weeks, diabetes+lactobacillus BB1 group. At the same time, mice of normal control group and diabetic group were subjected to intragastric administration of an equal volume of physiological saline daily.
The sugar preference experiment is carried out on each group of mice, two identical drinking water bottles are placed in each cage, one bottle is sucrose solution, the concentration is set to be 1, 5, 10, 15, 20, 25 and 50mmol/L respectively, the other bottle is deionized water, the solution amounts in the two bottles are kept consistent, the double-tube position is exchanged once every 24 hours for avoiding errors caused by position preference, and each sugar solution concentration is tested for 48 hours. The concentration of the solution was measured from low to high. The results showed that diabetic mice had a reduced preference for lower concentration sucrose solutions compared to normal mice, whereas feeding lactobacillus BB1 significantly increased their preference for lower concentration sucrose solutions, and it was seen that diabetic mice had a reduced sweet perception, whereas lactobacillus BB1 increased the sweet perception of diabetic mice (fig. 8).
The above preferred embodiments of the present invention are not limited to the above examples, and the present invention is not limited to the above examples, but can be modified, added or replaced by those skilled in the art within the spirit and scope of the present invention.
Claims (10)
1. Use of lactobacillus (Lactobacillus Firm-5) BB1 for the preparation of a medicament or feed additive for improving the perception of sweetness, characterized in that said lactobacillus BB1 has a deposit number GDMCC No. 61578.
2. The use according to claim 1, wherein the effect of improving sweetness perception comprises the following effects:
(1) Reducing the content of glutamine and serine in the hindgut and haemolymph of the individual;
(2) Altering neurotransmitter content in the brain of an individual.
3. The use of claim 2, wherein the effect of altering neurotransmitter levels in the brain of the individual comprises: up-regulating neurotransmitters acetylcholine, L-tyrosine, gamma-aminobutyric acid and/or putrescine, down-regulating neurotransmitters L-alanine and/or 5-hydroxytryptamine.
4. Use according to claim 1Characterized in that the viable count of the lactobacillus BB1 in the medicament is not less than 1×10 6 CFU/mL or 1X 10 6 CFU/g。
5. A medicament for improving the sweet taste perception capability of an individual, which is characterized in that the medicament contains lactobacillus BB1 with the preservation number of GDMCC No. 61578.
6. Use of lactobacillus BB1 for the preparation of a medicament for the prevention and/or treatment of obesity or for the regulation of blood glucose in obese patients, characterized in that said lactobacillus BB1 has the accession number GDMCC No. 61578.
7. Use of lactobacillus BB1 for the preparation of a medicament for regulating blood glucose in an individual, wherein said lactobacillus BB1 has a accession number of GDMCC No. 61578.
8. Use of lactobacillus BB1 for the preparation of a medicament for alleviating and treating taste deterioration in an individual, wherein said lactobacillus BB1 has accession number GDMCC No. 61578.
9. The use according to claim 8, characterized in that the use comprises the following actions: up-regulating mRNA expression of sweet taste receptors T1R2, T1R3 in an individual.
10. A pharmaceutical additive, characterized in that the pharmaceutical additive contains lactobacillus BB1 with the preservation number of GDMCCNo 61578.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311741875.2A CN117815276A (en) | 2023-12-18 | 2023-12-18 | Application of lactobacillus BB1 for improving sweet perception capability |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311741875.2A CN117815276A (en) | 2023-12-18 | 2023-12-18 | Application of lactobacillus BB1 for improving sweet perception capability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117815276A true CN117815276A (en) | 2024-04-05 |
Family
ID=90505181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311741875.2A Pending CN117815276A (en) | 2023-12-18 | 2023-12-18 | Application of lactobacillus BB1 for improving sweet perception capability |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117815276A (en) |
-
2023
- 2023-12-18 CN CN202311741875.2A patent/CN117815276A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| An et al. | Antiobesity and lipid-lowering effects of Bifidobacterium spp. in high fat diet-induced obese rats | |
| US8343482B2 (en) | Bifidobacterium longum and hippocampal BDNF expression | |
| RU2629806C2 (en) | Bacterial strains, belonging to bifidobacterium genus for application in hypercholesterinemia treatment | |
| CN113382740A (en) | Compositions comprising bacterial strains | |
| EA015461B1 (en) | Use of probiotic bacteria for food, feed and medicinal products | |
| TWI673057B (en) | Novel Lactobacillus paracasei strain | |
| CN112980725B (en) | Bifidobacterium lactis and application thereof in promoting growth and development of children and teenagers | |
| BR112018000934B1 (en) | Uses of bifidobacterium longum to treat or prevent depressive symptoms | |
| JP5674741B2 (en) | Probiotics used to relieve symptoms associated with digestive disorders | |
| CN110692885A (en) | Probiotic health-care beverage for relieving constipation | |
| WO2022269539A1 (en) | Method for favoring wellness and facilitating self-control before, during and/or after a restrictive diet | |
| TW201705969A (en) | Novel Lactobacillus mali APS1 and use thereof | |
| WO2020118576A1 (en) | Use of lactobacillus plantarum twk10 in preparation of composition for resistance to post-exercise inflammation or for reducing body fat | |
| CN114680171B (en) | Fermented milk for regulating intestinal health and preparation method thereof | |
| Bessa et al. | Kefir as a therapeutic agent in clinical research: a scoping review | |
| CN117815276A (en) | Application of lactobacillus BB1 for improving sweet perception capability | |
| US20190091270A1 (en) | Probiotics for use in relieving symptoms associated with gastrointestinal disorders | |
| Unsal et al. | The effects of food restriction on some biochemical parameters and certain bacterial groups in the cecum in Sprague Dawley rats | |
| KR20240118626A (en) | Composition for improving intestinal function comprising Lactiplantibacillus plantarum Y7 | |
| Баті et al. | Personalised diet imProve intestine microbiota and metabolism of obese rats | |
| CN118697770A (en) | Use of Lactobacillus paracasei 207-27 for regulating mood | |
| JP2024529268A (en) | Compositions containing three strains of Lactobacillus genus and uses thereof | |
| Chowdhury et al. | Isolation and Characterization of Probiotic Strain from Traditional Fermented Food | |
| CN118402554A (en) | Compound starter, fermented milk and preparation method thereof | |
| US20120177622A1 (en) | Renal-function-ameliorating agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |